文献速递肿瘤 PET/CT

68Ga-FAPI-46与18F-FDG PET/CT在晚期上皮性卵巢癌中的对比分析

Comparative analysis of 68Ga-FAPI-46 PET/CT and 18F-FDG PET/CT in advanced epithelial ovarian cancer: implications for preoperative scoring and treatment planning.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2026-01-05

本研究纳入41例初治晚期上皮性卵巢癌患者,均行18F-FDG与68Ga-FAPI-46 PET/CT检查,比较两种显像的诊断准确性、分期及治疗决策影响。68Ga-FAPI-46 PET/CT在腹膜和淋巴结转移检测上优于18F-FDG,使22%患者分期上调、17.1%治疗决策改变。

要点

  • 68Ga-FAPI-46 PET/CT对腹膜和淋巴结转移的敏感性、特异性及准确性优于18F-FDG。
  • 68Ga-FAPI-46 PET/CT使22%(9/41)患者分期上调,39%(16/41)评分改变。
  • 68Ga-FAPI-46 PET/CT影响17.1%(7/41)患者的治疗决策。

核心结论

  • 68Ga-FAPI-46 PET/CT在腹膜和淋巴结转移检测上优于18F-FDG,为晚期上皮性卵巢癌临床分期提供更准确参考,并可能改变近20%患者的治疗决策。

研究设计与样本

  • 前瞻性研究纳入2022年7月至2024年2月间41例初治晚期上皮性卵巢癌患者,每例均行18F-FDG和68Ga-FAPI-46 PET/CT检查。

主要发现

  • 腹膜转移相关PET/CT参数(GTV、SUVmax、TLG(FDG)、TL-FAPI)在两种显像间差异有统计学意义(P < 0.001)。
  • 68Ga-FAPI-46 PET/CT的PCI评分和敏感性高于18F-FDG PET/CT(P = 0.03)。
  • 68Ga-FAPI-46 PET/CT对盆腔、腹主动脉旁及腹外淋巴结诊断的敏感性、特异性和总体准确性均优于18F-FDG PET/CT。
  • 应用68Ga-FAPI-46 PET/CT后,22%(9/41)患者肿瘤分期上调,39%(16/41)患者PET/CT评分改变,17.1%(7/41)患者治疗决策受影响。
  • 在初次减瘤术(PDS)患者中,ROC分析显示18F-FDG PET/CT的GTV(AUC = 0.784, P = 0.018)、68Ga-FAPI-46 PET/CT的GTV(AUC = 0.809, P = 0.010)及TL-FAPI(AUC = 0.809, P = 0.010)对不完全切除有预测价值。

临床怎么用

  • 对晚期上皮性卵巢癌患者,68Ga-FAPI-46 PET/CT可更准确评估腹膜和淋巴结转移,辅助临床分期。
  • 68Ga-FAPI-46 PET/CT可能改变部分患者的治疗决策,有助于选择更合适的治疗策略。
  • GTV和TL-FAPI等参数可用于预测初次减瘤术不完全切除的风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To evaluate the clinical impact of 18F-FDG PET/CT versus 68Ga-FAPI-46 PET/CT in patients with advanced epithelial ovarian cancer (EOC), this study aims to investigate preoperative scoring criteria and establish a basis for the formulation of treatment plans tailored to this patient population. METHODS: A total of forty-one treatment-naive patients with advanced epithelial ovarian cancer were recruited for this study between July 2022 and February 2024. Each participant underwent both 18F-FDG and 68Ga-FAPI-46 PET/CT imaging. The study compared the diagnostic accuracy, PET/CT parameters, tumor staging, and the guidance provided for clinical treatment decisions by these two imaging modalities. Additionally, the tumor burden as assessed by both imaging techniques was evaluated to predict the likelihood of achieving R0 resection in subsequent surgical procedures. RESULTS: In the context of peritoneal metastasis, various PET/CT parameters were analyzed, including Gross Tumor Volume (GTV), SUVmax, Total Lesion Glycolysis (TLG(FDG)), and Total Lesion-FAPI (TL-FAPI). The comparative analysis of the two imaging modalities revealed statistically significant differences (P < 0.001). 68Ga-FAPI-46 PET/CT showed a higher PCI score and better sensitivity than 18F-FDG PET/CT (P = 0.03). Notably, the diagnostic accuracy of 68Ga-FAPI-46 PET/CT for detecting pelvic, para-aortic, and extra-abdominal lymph nodes was superior to that of 18F-FDG PET/CT, demonstrating enhanced sensitivity, specificity, and overall accuracy. Following the application of 68Ga-FAPI-46 PET/CT, tumor stages were upgraded in 22% (9 out of 41) of patients, while 39% (16 out of 41) exhibited alterations in their PET/CT scores relative to 18F-FDG PET/CT. Furthermore, the implementation of 68Ga-FAPI-46 PET/CT influenced treatment decisions in 17.1% (7 out of 41) of cases. For patients undergoing primary debulking surgery (PDS), receiver operating characteristic (ROC) curve analysis indicated that the GTV derived from both 18F-FDG PET/CT (AUC = 0.784, P = 0.018) and 68Ga-FAPI-46 PET/CT (AUC = 0.809, P = 0.010), along with TL-FAPI (AUC = 0.809, P = 0.010), demonstrated predictive value for incomplete resection during EOC debulking surgery. CONCLUSION: In comparison to 18F-FDG, 68Ga-FAPI-46 PET/CT presents significant advantages in the detection of peritoneal and lymph node metastases, thereby providing a more accurate reference for the clinical staging of patients with advanced epithelial ovarian cancer. Importantly, 68Ga-FAPI-46 PET/CT has the potential to modify treatment decisions in nearly 20% of patients, facilitating the selection of more appropriate therapeutic strategies.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Wu M, Hao B, Chen Z, et al. Comparative analysis of 68Ga-FAPI-46 PET/CT and 18F-FDG PET/CT in advanced epithelial ovarian cancer: implications for preoperative scoring and treatment planning. Eur J Nucl Med Mol Imaging. 2026. PMID: 41486388. doi:10.1007/s00259-025-07721-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。